9.13
price up icon0.44%   0.04
after-market Dopo l'orario di chiusura: 8.94 -0.19 -2.08%
loading
Precedente Chiudi:
$9.09
Aprire:
$9.04
Volume 24 ore:
553.85K
Relative Volume:
0.55
Capitalizzazione di mercato:
$460.05M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-1.7357
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
+5.06%
1M Prestazione:
+6.66%
6M Prestazione:
+15.86%
1 anno Prestazione:
-33.06%
Intervallo 1D:
Value
$8.78
$9.18
Intervallo di 1 settimana:
Value
$8.14
$9.18
Portata 52W:
Value
$5.035
$15.36

Regenxbio Inc Stock (RGNX) Company Profile

Name
Nome
Regenxbio Inc
Name
Telefono
240-552-8181
Name
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Dipendente
353
Name
Cinguettio
@REGENXBIO
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
RGNX's Discussions on Twitter

Confronta RGNX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RGNX
Regenxbio Inc
9.13 431.83M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-11 Downgrade Goldman Buy → Neutral
2025-02-07 Ripresa Raymond James Outperform
2024-11-15 Ripresa Morgan Stanley Overweight
2024-10-10 Ripresa Raymond James Outperform
2024-06-07 Iniziato Goldman Buy
2024-03-11 Iniziato H.C. Wainwright Buy
2024-03-08 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2024-03-06 Aggiornamento Leerink Partners Market Perform → Outperform
2024-02-21 Ripresa Raymond James Outperform
2023-11-01 Iniziato Stifel Buy
2023-06-02 Iniziato Robert W. Baird Outperform
2022-06-23 Iniziato Berenberg Buy
2021-12-15 Iniziato Wedbush Neutral
2021-10-19 Ripresa Morgan Stanley Overweight
2021-01-06 Aggiornamento Raymond James Outperform → Strong Buy
2020-12-16 Iniziato UBS Buy
2020-06-25 Ripresa BofA/Merrill Buy
2020-05-13 Iniziato RBC Capital Mkts Sector Perform
2019-08-20 Aggiornamento SVB Leerink Underperform → Mkt Perform
2019-06-18 Reiterato Chardan Capital Markets Buy
2019-06-14 Ripresa Raymond James Outperform
2019-06-05 Reiterato Chardan Capital Markets Buy
2019-02-25 Aggiornamento Evercore ISI In-line → Outperform
2019-02-05 Aggiornamento Raymond James Outperform → Strong Buy
2018-12-17 Reiterato Chardan Capital Markets Buy
2018-11-08 Reiterato BofA/Merrill Neutral
2018-08-08 Reiterato Chardan Capital Markets Buy
2018-07-23 Downgrade BofA/Merrill Buy → Neutral
2018-07-10 Reiterato Chardan Capital Markets Buy
2018-05-09 Reiterato Barclays Overweight
2018-04-09 Reiterato Chardan Capital Markets Buy
2018-03-12 Downgrade Evercore ISI Outperform → In-line
2018-02-13 Iniziato Mizuho Neutral
2017-11-09 Ripresa Morgan Stanley Overweight
Mostra tutto

Regenxbio Inc Borsa (RGNX) Ultime notizie

pulisher
Jul 24, 2025

What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives REGENXBIO Inc. stock priceOverwhelming profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 11, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Jul 11, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News

Jul 10, 2025
pulisher
Jul 09, 2025

Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com

Jul 09, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛

Jul 08, 2025
pulisher
Jun 16, 2025

Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 09, 2025

Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks

Jun 09, 2025
pulisher
Jun 07, 2025

REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Duchenne gene therapy interim trial outcomes "striking" - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive

Jun 06, 2025
pulisher
Jun 06, 2025

RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter

Jun 06, 2025
pulisher
Jun 05, 2025

REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech

Jun 05, 2025
pulisher
Jun 05, 2025

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview

Jun 05, 2025
pulisher
Jun 05, 2025

Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg

Jun 05, 2025

Regenxbio Inc Azioni (RGNX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):